Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADG106 |
Synonyms | |
Therapy Description |
ADG106 is an activating monoclonal antibody to TNFRSF9 (CD137) (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADG106 | ADG-106|ADG 106 | TNFRSF9 Antibody 32 | ADG106 is an activating monoclonal antibody to TNFRSF9 (CD137) (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03707093 | Phase I | ADG106 | Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | Completed | USA | 0 |